No. Singulair is a long-term controller medication and does not provide rapid relief. Patients experiencing an acute asthma exacerbation should use a fast-acting bronchodilator such as salbutamol.
Montelukast has been assigned a pregnancy category B in the UK, indicating no evidence of fetal risk in animal studies but limited human data. It should only be used when the potential benefit justifies any possible risk, after discussion with a prescriber.
If you remember the missed dose more than 8 hours before the next scheduled dose, take it immediately. If it is closer to the next dose, skip the missed one and continue with your regular schedule. Do not double-dose.
No specific foods or beverages need to be avoided. The tablet can be taken with or without meals.
Inhaled corticosteroids act directly on airway inflammation through anti-inflammatory pathways, while Singulair blocks leukotriene-mediated inflammation systemically. Both can be part of an asthma control regimen, but they operate via different mechanisms.
Weight gain is not a recognized side effect of montelukast. Report any unexpected changes in weight to your healthcare provider, as they may be unrelated to the medication.
Accidental overdose is rare because tablets are modestly dosed. Overdose symptoms may include severe headache, drowsiness, or abdominal discomfort. Seek emergency medical care if an overdose is suspected.
Routine blood monitoring is not required for most patients. However, individuals with pre-existing liver disease may need periodic liver-function tests at their clinician’s discretion.
There are no well-documented interactions with popular herbal products, but grapefruit juice can affect CYP3A4 enzymes and might modestly increase montelukast levels. Discuss all supplements with your prescriber.
The expiry date is printed on the packaging and is usually 24 months from the manufacturing date when stored correctly. Do not use tablets beyond this date.
Singulair is a brand-name medication that contains montelukast as its active component. Montelukast belongs to the class of leukotriene-receptor antagonists and is prescribed primarily for the management of asthma and allergic rhinitis. In the United Kingdom, Singulair is a prescription-only (POM) product regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as an oral pill in three strengths: 4 mg, 5 mg, and 10 mg.
Montelukast blocks the action of cysteinyl leukotrienes, which are inflammatory chemicals released by mast cells after exposure to allergens or irritants. By occupying leukotriene receptors in the airways, the drug:
These actions help prevent asthma symptoms and relieve nasal congestion caused by allergic rhinitis. Onset of effect typically occurs within a few hours, and the therapeutic benefit is maintained with once-daily dosing.
Approved indications in the UK (MHRA) include:
Singulair is not indicated for acute asthma attacks; a rapid-acting bronchodilator (e.g., a short-acting β₂-agonist) must be used for relief of sudden symptoms.
These events are usually transient and resolve without medical intervention.
Montelukast is metabolised primarily by CYP2C9, CYP3A4, and CYP2C8. Clinically relevant interactions are uncommon, but be aware of:
General advice: Patients should disclose all prescription drugs, over-the-counter medicines, herbal supplements, and vitamins to their prescriber before starting Singulair.
Administration tips
Routine follow-up appointments should be scheduled at least every 3 months after initiation, or sooner if symptoms change.
This article provides educational information about Singulair and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
